| Quantification and characterization of human endothelial cell–derived tissue factor pathway inhibitor-2 M Iino, DC Foster, W Kisiel Arteriosclerosis, thrombosis, and vascular biology 18 (1), 40-46, 1998 | 125 | 1998 |
| Prognosis of patients with adult T‐cell leukemia/lymphoma in Japan: a nationwide hospital‐based study Y Imaizumi, M Iwanaga, K Nosaka, K Ishitsuka, K Ishizawa, S Ito, ... Cancer Science 111 (12), 4567-4580, 2020 | 62 | 2020 |
| Epitope location on tissue factor determines the anticoagulant potency of monoclonal anti-tissue factor antibodies D Kirchhofer, P Moran, N Chiang, J Kim, MA Riederer, C Eigenbrot, ... Thrombosis and haemostasis 84 (12), 1072-1081, 2000 | 62 | 2000 |
| Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking KA Lapan, PJ Fay Thrombosis and haemostasis 80 (09), 418-422, 1998 | 54 | 1998 |
| Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII M Iino, DC Foster, W Kisiel Archives of biochemistry and biophysics 352 (2), 182-192, 1998 | 49 | 1998 |
| Factor VII central: a novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor Xa, and abolishes amidolytic and coagulant activity D Bharadwaj, M Iino, M Kontoyianni, KJ Smith, DC Foster, W Kisiel Journal of Biological Chemistry 271 (48), 30685-30691, 1996 | 49 | 1996 |
| All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII G Bolt, TD Steenstrup, C Kristensen Thrombosis and haemostasis 98 (11), 988-997, 2007 | 41 | 2007 |
| Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis … M Iino, Y Sakamoto, T Sato International Journal of Hematology 112, 159-168, 2020 | 31 | 2020 |
| Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen M Iino, H Takeya, T Takemitsu, T Nakagaki, EC Gabazza, K Suzuki European journal of biochemistry 232 (1), 90-97, 1995 | 29 | 1995 |
| Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan Y Tsukune, M Sasaki, T Odajima, K Sunami, T Takei, Y Moriuchi, M Iino, ... Blood cancer journal 7 (12), 631, 2017 | 27 | 2017 |
| D-index–guided early antifungal therapy versus empiric antifungal therapy for persistent febrile neutropenia: a randomized controlled noninferiority trial Y Kanda, S Kimura, M Iino, T Fukuda, E Sakaida, T Oyake, H Yamaguchi, ... Journal of Clinical Oncology 38 (8), 815-822, 2020 | 26 | 2020 |
| The role of the factor X activation peptide: a deletion mutagenesis approach AE Rudolph, MP Mullane, R Porche-Sorbet, HA Daust, JP Miletich Thrombosis and haemostasis 88 (11), 756-762, 2002 | 23 | 2002 |
| Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site H Nakagawa, N Takahashi, K Fujikawa, Y Kawamura, M Iino, H Takeya, ... Glycoconjugate journal 12, 173-181, 1995 | 20 | 1995 |
| Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan H Koh, M Hino, K Ohta, M Iino, F Urase, M Yamaguchi, J Yamanouchi, ... Journal of Infection and Chemotherapy 19 (6), 1126-1134, 2013 | 17 | 2013 |
| The role of human factor X activation peptide in activation of factor X by factor IXa M Iino, H Takeya, J Nishioka, T Nakagaki, K Tamura, K Suzuki The Journal of Biochemistry 116 (2), 335-340, 1994 | 17 | 1994 |
| Clinical characteristics and outcomes in patients with t (8; 21) acute myeloid leukemia in Japan H Narimatsu, T Yokozawa, H Iida, M Tsuzuki, M Hayakawa, T Takeo, ... Leukemia 22 (2), 428-432, 2008 | 16 | 2008 |
| Clinical significance of minimal residual disease in patients with t (8; 21) acute myeloid leukemia in Japan H Narimatsu, M Iino, T Ichihashi, T Yokozawa, M Hayakawa, H Kiyoi, ... International journal of hematology 88, 154-158, 2008 | 15 | 2008 |
| Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia T Endo, Y Yatomi, N Amemiya, A Mizoe, M Iino, H Ozawa, S Hosogaya, ... American journal of hematology 63 (3), 145-148, 2000 | 15 | 2000 |
| Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution M Iino, T Yamamoto, Y Sakamoto Hematology 24 (1), 355-361, 2019 | 12 | 2019 |
| Screening for Gaucher disease using dried blood spot tests: a Japanese multicenter, cross-sectional survey T Miyamoto, M Iino, Y Komorizono, T Kiguchi, N Furukawa, M Otsuka, ... Internal Medicine 60 (5), 699-707, 2021 | 11 | 2021 |
Tomoki NaoeNagoya University, NHO Nagoya Medical CenterZweryfikowany adres z mail.hosp.go.jp